# ATG Plus Low-dose PT-Cy for GVHD Prevention

> **NCT06108739** · PHASE3 · TERMINATED · sponsor: **Peking University People's Hospital** · enrollment: 66 (actual)

## Conditions studied

- Hematologic Malignancy

## Interventions

- **DRUG:** Cyclophosphamid
- **DRUG:** ATG

## Key facts

- **NCT ID:** NCT06108739
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 66 (ACTUAL)
- **Why stopped:** DSMB recommended halting the study owing to futility after the first interim analysis in August 2024.
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06108739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06108739, "ATG Plus Low-dose PT-Cy for GVHD Prevention". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT06108739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*